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Abstract
The need to search for new, alternative treatments for various diseases has prompted scientists and physicians to focus their
attention on regenerative medicine and broadly understood cell therapies. Currently, stem cells are being investigated for
their potentially widespread use in therapies for many untreatable diseases. Nowadays modern treatment strategies willingly
use mesenchymal stem cells (MSCs) derived from different sources. Researchers are increasingly aware of the nature of MSCs
and new possibilities for their use. Due to their properties, especially their ability to self-regenerate, differentiate into several
cell lineages and participate in immunomodulation, MSCs have become a promising tool in developing modern and efficient
future treatment strategies. The great potential and availability of MSCs allow for their various clinical applications in the
treatment of many incurable diseases. In addition to their many advantages and benefits, there are still questions about the use
of MSCs. What are the mechanisms of action of MSCs? How do they reach their destination? Is the clinical use of MSCs safe?
These are the main questions that arise regarding MSCs when they are considered as therapeutic tools. The diversity of MSCs,
their different clinical applications, and their many traits that have not yet been thoroughly investigated are sources of dis-
cussions and controversial opinions about these cells. Here, we reviewed the current knowledge about MSCs in terms of their
therapeutic potential, clinical effects and safety in clinical applications.
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Introduction
In the 1960s, Friedenstein et al. identified a population of
fibroblast-like cells that formed clonal colonies in vitro
(CFU-F, Colony Forming Unit-Fibroblast)1. Friedenstein’s
observations allowed for the discovery of a specific type of
cell, currently referred to as mesenchymal stem cells
(MSCs). MSCs are primary, non-specialized, nonhemato-
poietic, plastic adherent cells with great proliferation poten-
tial and the capacity for self-renewal and differentation2.
In 2006, the International Society of Cellular Therapy
(ISCT) proposed basic criteria for defining human multipo-
tent mesenchymal stromal cells whose name then evolved to
MSCs. In addition to their plastic adherent properties under
standard culture conditions and trilineage differentiation
capacity into osteoblasts, chondrocytes and adipocytes,
> 95% of the MSCs population is positive for the three
specific surface markers—CD73 (SH3/4), CD90 (Thy-1),
and CD105 (SH2)—and do not express CD45, CD34,
CD14, CD11b, CD79a, CD19, or major histocompatibility
complex (MHC) class II3,4. MSCs also express others mar-
kers, including CD9, CD10, CD13, CD29, CD44, CD49,
CD51, CD54 (ICAM-1), CD117 (c-kit), CD146 (MCAM),
CD166 (ALCAM), and Stro-1, but the expression of specific
combinations of the markers appear to be host tissue depen-
dent5. Although a wide range of positive markers describing
MSCs has been identified, no single marker has been indi-
cated as specific for MSCs.
It should be also noted that the potential of MSCs for
differentiation and proliferation may vary considerably
between different MSC sources6,7. It has been suggested that
these differences are a result of the direct influence of the
specific microenvironments in which they primarily reside8,9.
Despite increasing numbers of reports describing MSCs,
numerous controversies have arisen regarding the proper
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identification of MSCs. It appears that the criteria proposed
by the ISCT are not sufficient because MSCs isolated from
different tissues represent a relatively heterogeneous group
of cells in terms of differentiation, proliferation abilities, and
cell surface expression6,10–13.
Mesenchymal Stem Cells—the Main
Players in Cell Therapy
The fact that MSCs can be isolated from numerous
sources1,2,6–8,10 (Fig. 1), their relative ease to culture in vitro,
their ability to differentiate into several different cell types,
and their special immunological properties make MSCs a
promising tool for cell therapy and tissue regeneration. The
best known and the most commonly used source of MSCs is
bone marrow (BM)14. BM is the tissue in which MSCs were
first identified. Another easily accessible source of MSCs is
adipose tissue15. Obtaining MSCs from these sources
requires invasive procedures. Interestingly, rich sources of
MSCs include birth-associated tissues that are treated as
medical waste, such as placenta, umbilical cord, amniotic
fluid, and amniotic membrane. Among those tissues, umbi-
lical cord blood16 is believe to contain MSCs; however, the
use of this source is questioned by some researchers because
of low efficiency of their isolation17. MSCs derived from
Wharton’s jelly of the umbilical cord (WJ-MSCs) appear
to have great future clinical utility due to their limited het-
erogeneity and some unique properties, such as ease of their
isolation and culture, availability in several tissues, their
immunomodulatory properties, ability to self-regenerate,
differentiate into several cell lineages, and the lack of ethical
problems resulting from their use18. Moreover, in contrast to
BM or adipose tissue, the acquisition and isolation of birth-
associated tissues, including WJ-MSCs, do not require inva-
sive surgical procedures; therefore, the isolation process
does not pose any risk of complications for the donor, giving
them an advantage over other MSC sources. Currently, new
sources of MSCs have been proposed. MSCs are found in
dental pulp, periodontal ligament, tendon, skin, muscle, and
other tissues19 (Fig. 1). However, there are differences in
isolation efficiency that are related to the availability, con-
dition, and age of the donor tissue. A very important issue is
the age of the donor’s cells20. Cells obtained from younger
donors are less susceptible to oxidative damages and
changes, they age considerably more slowly in culture, and
they have a higher proliferation rate21,22.
Currently, many studies focus on the use of MSCs in cell
therapy. MSCs are used as a tool to treat degenerative
changes in joints and to reconstruct bones and cartilage,


































Fig. 1. Mesenchymal stem cells sources.
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cardiovascular diseases, endocrine and nervous system dis-
eases, cell transplantation, and in the repair of damaged
musculoskeletal tissues23. Due to the special properties of
these cells, such as their rapid proliferation, high differentia-
tion capacity, and the ability to migrate into the site of
damage, new clinical applications are being tested.
BM-MSCs are the most frequently used in clinical set-
tings24. BM-MSCs were also first to be registed by the Food
and Drug Administration as a drug against Graft versus Host
Disease called “Prochymal”25. Recently, “Alofisel” has been
registered by the European Medicines Agency to treat com-
plex perianal fistulas. The drug is based on expanded
adipose-derived stem cells26. In both cases the drugs are
allogeneic, which provides strong advantage other autolo-
gous products due to possibility of detailed testing regarding
both safety and potency before release. Nowadays other
sources of MSCs are also used for clinical therapies. Our
research group used MSCs isolated from Wharton Jelly to
treat patients with acute myocardial infarction, showing the
safety and feasibility of such therapy27. Currently, we are
conducting phase II/III randomized, double-blinded clinical
trials with the use of the product “CardioCell” that is based
on WJ-MSCs in three indications: acute myocardial infarc-
tion (AMI-Study, EudraCT Number: 2016-004662-25),
chronic ischemic heart failure (CIHF-Study, EudraCT Num-
ber: 2016-004683-19), and non-option critical limb ischemia
(N-O CLI-Study, EudraCT Number: 2016-004684-40).
However, it should be noted that although we possess
great knowledge about their in vitro characteristics, we still
know much less about the in vivo behaviors of MSCs. They
can act both directly—due to their ability to differentiate28—
and indirectly, by producing and secreting many factors
that enhance the endogenous regeneration potential of
injured tissue19.
The new approach in stem cell therapy is the use of extra-
cellular vesicles (EVs), which can be used as a substitute for
MSCs29. EVs as a therapeutic vector have the paracrine
effect without the direct involvement of the cells. They are
released from stem cells and they supply many components
such as mRNA, DNA, and proteins to the target site30. This
approach is described in many recent studies31,32 but a thor-
ough understanding of the mechanism of action of EVs is
still required.
Migration and Homing of Mesenchymal
Stem Cells
The therapeutic effect of MSCs depends on their ability to
reach the injured site, which is possible due to their ability to
migrate, adhere, and engraft into a target tissue. Several
factors affect the therapeutic efficacy of MSCs’ homing.
Among them, culture conditions, the number of passages,
donor age, delivery method, and host receptibility play
important roles33–36. It has been shown that freshly isolated
cells compared with in vitro-cultured cells have a higher
engraftment efficiency37, which can be a result of the
aging/differentiation process that cells undergo in in vitro
culture conditions38,39. Culture conditions also have a sig-
nificant impact on homing capacity, as they can modify the
expression of the surface markers involved in this process.
As an example, CXCR4, a chemokine receptor, is involved
in the migration of MSCs. It has been shown that CXCR4
expression is lost on BM-MSCs during culture37,40,41,
whereas the presence of cytokines (e.g., HGF, IL-6), hypoxic
conditions, or direct introduction using viral vectors allow
for restoration of its expression42–44.
In addition, MSCs isolated from older donors show
altered compositions and functions of membrane glycero-
phospholipids45. All of these aspects affect MSCs’ ability
to migrate, home, and engraft into a site of injury.
The efficacy of cell therapy largely depends on the deliv-
ery method. The most common method of administration of
MSCs is intravenous infusion46–48. However, before the cells
reach their target, the majority are trapped within capillaries
of various organs, especially in the lungs46,49–52. This
attrition can be explained by the fact that MSCs are rela-
tively large cells and express various adhesion molecules.
Despite the fact that MSCs can become trapped in the lungs,
numerous pieces of evidence suggest that they are able to
home to injured tissue50,53. Interestingly, recent data also
suggest that despite the problems associated with intrave-
nous infusions, this route results in similar efficacy as other
modes of delivery of MSCs54. In some instances, intra-
arterial injection seems to be a more effective route. It has
been shown that delivery of MSCs through the internal car-
otid artery more effectively facilitates their migration and
homing into injured brain compared with administration via
the femoral vein. The risk associated with this route of deliv-
ery includes occlusions, which can arise in microvessels53.
When the MSCs were delivered directly to the heart, near the
damaged area, the number of cells that reached the peri-
infarct region was much higher55.
As has already been mentioned, the necessary condition
for effective MSC-based therapy is for the cells to reach the
site of injury and home to the affected tissue. There is no
doubt that specific receptors and adhesion molecules and
interactions with endothelial cells play crucial roles in this
migration and homing. Cell adhesion proteins are expressed
in the plasma membrane, such as integrins, which are
involved in cell adhesion to extracellular matrix proteins
(EMC), such as collagen, fibronectin, and laminin38,56–60.
In vivo studies have shown that MSCs exhibit chemotactic
properties and, after intravenous injections, are able to attach
to endothelium and migrate between endothelial cells toward
injured tissue in response to factors that are upregulated
under the inflammatory conditions61–64. However, the
detailed mechanisms of their transendothelial migration
(TEM), diapedesis, and homing to sites of injury and inflam-
mation have not yet been explained in detail. It is presumed
that this mechanism may be similar to that of leukocytes
(Fig. 2)65–67 but is performed with the participation of dif-
ferent adhesion molecules. To date, many chemokines and
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growth factors have been identified (e.g., EGF, VEGF-A,
FGF, PDGF-AB, HGF, TGF-b1, TNF-a, SDF-1a, IL-6,
IL-8, IGF-1), including their receptors, adhesion molecules,
and metalloproteinases, that are involved in the MSCs
migration process (e.g., CXCL-12, CCL-2, CCL-3, CCR4,
CXCR4, VCAM, ICAM)55,59,65,68–71. Many reports suggest
that damaged tissue expresses specific factors that act as
chemoattractants to facilitate the migration, adhesion, and
infiltration of MSCs to sites of injury, as in the case of
leukocytes trafficking to sites of inflammation. However,
although the leukocyte recruitment process (i.e., binding to
endothelial cells, rolling, adhesion, and TEM) is well
understood, the mechanism of the interaction between
MSCs and endothelial cells will require more detailed
investigations. Studies by Rüster et al. showed that the
ability of MSCs to bind and roll on endothelial cells was
derived from human umbilical cord vein cells. Once the
MSCs adhere to endothelium, they become shaped like
protrusions and roll. The molecules involved in this process
have been identified and include P-selectin and VLA-4
expressed on MSCs and VCAM-1 on endothelial cells
(VLA-4/VCAM-1 interaction)65. It has also been con-
firmed that a vital role in the homing and migration of
MSCs is played by the proteolytic enzymes matrix metal-
loproteinases (MMPs)37,41.
Immunological Properties of Mesenchymal
Stem Cells
It is generally accepted that MSCs do not display immuno-
genic properties, so they can be transplanted to an allogenic
host without need for immunosuppression. The mechanism
of their action is based on their immunomodulatory proper-
ties as well as immunosuppressive activity. They are able to
suppress proliferation and activation of different cells of the
immune system. These interactions may occure directly (i.e.,
cell–cell interaction) and indirectly (via soluble factors), and
this pathway of suppression is independent of MHC match-
ing between MSCs and T cells 39,72,73. The immunomodulat-
ing effect of MSCs is reflected in many T-cell properties,
such as activation and proliferation, and in this way they
efficiently suppress an immune response73. The MSCs sup-
press the proliferation of activated T cells by secreting sub-
stances, such as indoleamine 2,3-dioxygenase (IDO) and
prostaglandin E2 (PGE2)74–76. They also suppress the devel-
opment of pro-inflammatory Th17 cells and stimulate reg-
ulatory T cells by secreting immunosuppressive cytokines
including IL-6, IL-8, IL-10, TGF-b, and HGF. In addition,
the nonclassical HLA class I molecules (HLA-G) expressed
by MSCs exert immunosuppressive effects on various
immune cells; that is, they inhibit T-cell proliferation and
cytotoxic T lymphocyte-mediated cytolysis, and they also
induce the development of tolerogenic dendritic cells and
inhibit natural killer cell cytolytic functions77–80. It has been
shown that HLA-G contributes to decrease graft rejection81.
MSCs also participate in regulation of Th1/Th2 balance (T
helper cells) by affecting the level of interleukin-4 (IL-4) and
interferon (IFN)-g in effector T cells. MSCs disturb matura-
tion, differentiation, and functions (i.e. cytokine secretion)
of dendritic cells (DCs), which play a crucial role in antigen
presentation. There is much evidence that MSCs inhibit the
proliferation, differentiation, and chemotaxis of B
cells75,82,83. They also prevent monocyte differentiation into









Fig. 2. Schematic of leukocyte transmigration through the endothelium. It is supposed that MSCs migration occurs in a similar manner.
The graphic was prepared using modified art elements from Servier Medical Art, found at https://smart.servier.com.
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protected against cell lysis and the cytotoxic effects of the
host’s immune system.
The immunophenotype of MSCs is generally described
as: MHC Iþ, MHC II-. They also do not express the costi-
mulatory molecules (CD40, CD80, CD86) and hematopoie-
tic markers CD45, CD34, CD14, CD11, CD19, and CD18
(LFA-1; leukocyte function-associated antigen-1), which
makes them non-immunogenic. MHC class I may activate
T cells, but with the absence of costimulatory molecules, the
T cells are non-reactive84–88.
Safety of Mesenchymal Stem Cell
Therapies
Many studies have been conducted thus far to investigate
the safety of MSC-based therapies. Clinical trials show
that in vitro-cultured human MSCs are less susceptible to
adverse changes.
A Canadian group analyzed clinical trials in which BM-
MSCs were used. After a thorough analysis of 36 studies, they
found that there was no relationship between the use of MSCs
and tumorigenic potential, and no serious side effects of the
therapy were reported89. The safety and impact of MSCs ther-
apy were also investigated by Karussis et al. in patients with
multiple sclerosis and amyotrophic lateral sclerosis90. In 34
examined patients, during a study lasting 25 months, no serious
adverse effects resulting from the therapy were observed. In
addition, 20 patients were examined 1 year after transplanta-
tion, and the MRI results did not show any disturbing
changes90. However, more long-term studies and observations
regarding the safety of using MSCs therapies will be required.
However, one study reported that the use of autologous
adipose tissue-derived MSCs (AT-MSCs) in a patient with
chronic kidney disease resulted not only in the improvement
of renal function but also in fibrosis of the interstitial tissue
and atrophy of the tubules, which could suggest nephrotoxi-
city of the applied MSCs91. Another group investigated the
efficacy of the allogeneic treatment of MSCs administered to
the aortas of patients with acute kidney injury after cardiac
surgery. No differences were observed between the treated
group and the control group in terms of improvement of
renal function or in the occurrence of adverse events92.
Tatsumi et al. demonstrated in an in vivo model that the
administration of AT-MSCs may result in thrombus forma-
tion around the cells through a coagulation mechanism,
which can also cause pulmonary embolism due to the accu-
mulation of cells in the lung region93. This finding was con-
firmed by other studies performed using umbilical cord
MSCs, which showed the procoagulant properties of these
cells after peripheral vein injection94. Many researchers cur-
rently focus on thromboinflammation, also known as the
instant blood-mediated inflammatory reaction, which can
occur after transplantation of MSCs95,96. Taking into
account all of these issues, it is clear that more long-term
studies and observations regarding the safety of using MSCs
are required.
Despite the many cons for using MSCs in clinical set-
tings, there are still a few issues that need to be resolved for
the successful application of MSCs. One of them involves
obtaining sufficient numbers of the cells. Unfortunately, dur-
ing in vitro culture, cells at higher passages age due to
decreased telomerase activity97. In addition, during long-
term culture, MSCs lose their potential to differentiate and
begin to exhibit morphological changes98. Even more impor-
tantly, long-term culture might lead to the increased prob-
ability of malignant transformation99,100. Certain
components of the culture medium and growth factors may
predispose the cells to such processes. There is also a risk of
viral and prion transmission after administration of the
cells101.
The Dark Side of Mesenchymal Stem
Cell Biology
When using stem cell-based therapies, all possible undesir-
able effects should be considered. The risk associated with
tumorigenesis after stem cell transplantation is widely dis-
cussed in the literature. In a certain sense, stem cells can be
compared to tumor cells because of their ability to prolifera-
tion for a long period of time, high viability, and resistance to
apoptosis102. Many components may affect the potential
tumorigenesis after MSCs transplantation, including the
donor’s age, host tissue, growth regulators expressed by
recipient tissue, and mechanisms that control the behavior
of the MSCs at the target site103–105. Also, manipulations
and long-term in vitro cultures of MSCs can cause genetic
instability and chromosomal abberations105. Many
cumulative factors can give a response in the form of a
spontaneous tumor transformation. Patients who are trans-
planted with stem cells often undergo long-term che-
motherapy or radiotherapy, so their immune system
does not work properly, which may also be associated
with the risk of tumorigenesis106.
Protumorigenic Effect of Mesenchymal
Stem Cells
The direct role of MSCs in promoting tumorigenesis has
been investigated by several research groups in animal
models. Results obtained for BM-MSCs show that the
cells can engraft and home to many different types of
solid tumors107–111. MSCs have been injected simultane-
ously with tumor cells in vivo. BM-MSCs promoted
tumor growth in a colon cancer model109 and in breast
cancer108, colorectal cancer112, ovarian113, prostate114,
lung107, and gastric carcinoma115.
A highly complex tumorigenesis process involves many
factors that promote tumor growth, one of which is
hypoxia116. The published data indicate that BM-MSCs can
be associated with tumor progression by the secretion of
proangiogenic factors107.
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MSCs have also been examined in the tumorigenic
context due to the identification of carcinoma-associated
fibroblast (CAF) cells, tumor-associated fibroblast (TAF)
cells, and other tumor-associated cells, such as endothe-
lial and pericyte-like cells, since MSCs can differentiate
into these cell types under appropriate conditions117. In
vitro and in vivo studies have shown that BM-MSCs cul-
tured together with tumor cells may adopt the CAF-like
phenotype, and the tumor microenvironment predisposes
the transformation of these cells into a-smooth muscle
actin (a-SMA)-expressing myofibroblasts118. Depending
on the research model used, the percentage of MSCs
taking part in this phenomenon varies. In an ovarian can-
cer model, it was found that the percentage of MSC-
derived CAF cells ranged from 60 to 70%, whereas in
the pancreatic cancer model, the percentage was only
approximately 20%.
In studies by Karnoub et al., mice were used to graft non-
metastatic breast cancer cells together with MSCs (BM-
MSCs)108. The results of this study showed that, compared
with mice injected only with cancer cells, the mix of MSCs
and cancer cells increased the metastasis potential. The spe-
cial engraftment properties and specific tropism of injected
GFP þ BM-MSCs into a mouse tumor model were also
shown by Ren et al.119. Interestingly, it has been shown that
the actions of stem cells (including nonhematopoietic and
hematopoietic stem cells) in combination with different
tumor cells can vary in vitro and in vivo. In vitro, MSCs
cells showed antiproliferative activity, stopping in the G1
phase, in contrast to in vivo studies, where MSCs caused
faster tumor growth120.
The Bright Side of Mesenchymal Stem Cell
Biology
MSCs display a dualistic nature in relation to their tumor-
igenicity. Some studies have also shown their anti-
tumorigenic effects. Factors secreted by MSCs may have
antitumor properties. Clarke et al. showed that breast cancer
cells cultured in MSC-conditioned medium exhibit signifi-
cant migratory inhibition compared with cells cultured in a
standard medium. The tumorigenesis effect of MSCs may be
exerted by the secretion of the proteins TIMP-1 and TIMP-2,
which inhibit the activity of the MMPs that are involved in
migration processes121.
The inhibition of tumor cell growth was also shown by
Bruno et al.122. A human hepatocellular carcinoma cell line
(HepG2), a human ovarian cancer cell line (Skov-3), and
Kaposi’s sarcoma cell lines co-cultured in the presence of
BM-MSCs exhibited reduced in vitro growth. In addition,
microvesicles (MVs) isolated from MSCs caused significant
decreases in tumor cell proliferation through inhibiting cell
cycle progression and inducing apoptosis and necrosis of the
tumor cells. These observations were confirmed by in vivo
studies in which tumor growth was slowed down by the
administration of BM-MSC-derived MVs122.
Similar data were obtained with MVs derived from human
WJ-MSCs. Wu et al. observed that WJ-MSC-derived MVs
down-regulated the phosphorylation of Akt protein kinase and
activated p53/p21 in bladder tumor cell lines123. Oxidative
stress, which occurs in damaged tissues, is a natural process
after the occurrence of damage. Therapies that use stem cells
mainly focus on the regeneration of damaged tissues. Thus,
the enhanced apoptotic resistance of MSCs, which is the result
of regulation of the apoptosis process through complex cel-
lular pathways, is highly desirable in the regeneration process
that is the result of MSC therapy102,124.
There is no unambiguous answer regarding the potential of
MSCs in tumorigenesis. In fact, the effect of MSCs depends
not only on the tumor model used but also on the method of
culture, cell heterogeneity, dose, secreted molecules, and
many other factors that have not yet been fully understood.
Other Restrictions Related to the
Application of Mesenchymal Stem Cells
Many studies (both preclinical and clinical trials) show
increasing evidence of the therapeutic effectiveness of
MSCs. However, many studies also provide evidence of low
engraftment of MSCs due to their short-lived viability after
injection125,126. It has also been demonstrated that after
MSCs are transplanted, many of them are trapped in the
lungs, resulting in a reduction in the population of cells that
occupy the target site127. However, portions of MSCs popu-
lations reach damaged tissue, such as infarcted myocardium,
traumatically injured brain, fibrotic liver, and various types
of tumors125. The method by which the cells are adminis-
tered may be an important factor in their reaching their
intended destination. The advantage of the targeted applica-
tion of these cells versus systemic administration is reduc-
tions in cell losses during delivery and cell migration128.
The low immunogenicity of the MSCs makes cell transplan-
tation well tolerated by the recipient organism, reducing the
likelihood of rejection of the transplantation. However, differ-
entiated MSCs may exhibit low or no therapeutic effects. Huang
et al. demonstrated that differentiated MSCs have increased
immunogenicity due to MHC-I and MHC-II expression129.
Most of the studies conducted show that a single trans-
plantation of MSCs is safe and does not induce an immune
response. However, repeated administration of MSCs may
result in the production of allo-antibodies130. Moreover, the
fetal bovine serum (FBS) used in the MSC culture medium
may cause an immune response in patients who have
received such cells. Von Bonin et al. showed that the trans-
plantation of MSCs that had been in contact with FBS
induced the production of antibodies against FBS in the
recipient’s blood131.
Concluding Remarks
Stem cells are undoubtedly a great hope for the treatment of
many diseases. Since they occur in many adult tissues and do
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not raise ethical issues, they have great advantages over
embryonic stem cells. Due to their unique features, such as
their ease of isolation and culture, availability in many tis-
sues, their immunomodulatory properties, and the lack of
ethical problems resulting from their use, we believe that
they can be used in both autologous and allogeneic trans-
plantations. Despite numerous in vitro and in vivo studies,
the mechanisms underlying MSCs transmigration and hom-
ing require further detailed examination. Nevertheless, there
is no doubt that the cells can migrate and home to injured
tissues. More research is emerging regarding the potential
long-term risks associated with MSCs therapy. Long-term
studies and observations will be necessary to investigate the
long-term effects of MSCs therapies, including the negative
effects. Based on our data, allogeneic clinical use of the
MSCs seems to be promising tool in regenerative medicine.
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history of mesenchymal stem cells, from vessel walls to culture
vessels. Cell Mol Life Sci. 2014;71(8):1353–1374.
20. Richardson SM, Kalamegam G, Pushparaj PN, Matta C,
Memic A, Khademhosseini A, Mobasheri R, Poletti FL,
Musiał-Wysocka et al 807
Hoyland JA, Mobasheri A. Mesenchymal stem cells in regen-
erative medicine: focus on articular cartilage and intervertebral
disc regeneration. Methods. 2016;99:69–80.
21. Wagner W, Bork S, Horn P, Krunic D, Walenda T, Diehlmann
A, Benes V, Blake J, Huber FX, Eckstein V, Boukamp P, Ho
AD. Aging and replicative senescence have related effects on
human stem and progenitor cells. Plos One. 2009;4(6):e5846,
1–13.
22. Stolzing A, Jones E, McGonagle D, Scutt A. Age-related
changes in human bone marrow-derived mesenchymal stem
cells: consequences for cell therapies. Mech Ageing Dev.
2008;129(3):163–173.
23. Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem
cells: environmentally responsive therapeutics for regenerative
medicine. Exp Mol Med. 2013;45:e54.
24. Wang LT, Ting CH, Yen ML, Liu KJ, Sytwu HK, Wu KK, Yen
BL. Human mesenchymal stem cells (MSCs) for treatment
towards immune- and inflammation-mediated diseases: review
of current clinical trias. J Biomed Sci. 2016;23(1):76–89.
25. Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D,
Broadwater G, Monroy R, Kurtzberg J. Efficacy and safety of
ex vivo cultured adult human mesenchymal stem cells
(Prochymal™) in pediatric patients with severe refractory
acute graft-versus-host disease in a compassionate use study.
Biol Blood Marrow Transplant. 2011;17(4):534–541.
26. Panés J, Garcı́a-Olmo D, Van Assche G, Colombel JF, Rein-
isch W, Baumgart DC, Dignass A, Nachury M, Ferrante M,
Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E,
Richard MP, Diez MC, Tagarro I, Leselbaum A, Danese S;
ADMIRE CD Study Group Collaborators. Long-term efficacy
and safety of stem cell therapy (Cx601) for complex perianal
fistulas in patients with Crohn’s disease. Gastroenterology.
2018;154(5):1334–1342.
27. Musialek P, Mazurek A, Jarocha D, Tekieli L, Szot W, Kost-
kiewicz M, Banys RP, Urbanczyk M, Kadzielski A, Trystula
M, Kijowski J, Zmudka K, Podolec P. Myocardial regeneration
strategy using Wharton’s jelly mesenchymal stem cells as an
offthe-shelf “unlimited” therapeutic agent: results from the
acute myocardial infarction first-in-man study. Adv Intervent
Cardiol. 2015;11:100–107.
28. Gojo S, Gojo N, Takeda Y, Mori T, Abe H, Kyo S, Hata JI,
Umezawa A. In vivo cardiovasculogenesis by direct injection
of isolated adult mesenchymal stem cells. Exp Cell Res. 2003;
288(1):51–59.
29. La Greca A, Solari C, Furmento V, Lombardi A, Biani MC,
Aban C, Moro L, Garcı́a M, Guberman AS, Sevlever GE,
Miriuka SG, Luzzani C. Extracellular vesicles from pluripotent
stem cell-derived mesenchymal stem cells acquire a stromal
modulatory proteomic pattern during differentiation. Exp Mol
Med. 2018;50(9):119–131.
30. Sabin K, Kikyo N. Microvesicles as mediators of tissue regen-
eration. Transl Res. 2014;163(4):286–295.
31. Bobis-Wozowicz S, Kmiotek K, Kania K, Karnas E, Labedz-
Maslowska A, Sekula M, Kedracka-Krok S, Kolcz J, Borucz-
kowski D, Madeja Z, Zuba-Surma EK. Diverse impact of
xeno-free conditions on biological and regenerative properties
of hUC-MSCs and their extracellular vesicles. J Mol Med.
2017;95(2):205–220.
32. Vonk LA, van Dooremalen SF, Liv N, Klumperman J, Coffer
PJ, Saris DBF, Lorenowicz MJ. Mesenchymal stromal/stem
cell-derived extracellular vesicles promote human cartilage
regeneration in vitro. Theranostics. 2018;8(4):906–920.
33. Pezzi A, Amorin B, Laureano Á, Valim V, Dahmer A, Zam-
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Bisset L, Büscher D, Fibbe W, Foussat A, Kwa M, Lantz O,
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